Akili (AKLI) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 07, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	Akili, Inc.
Entity Central Index Key	0001850266
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		77,908,746
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity File Number	001-40558
Entity Tax Identification Number	98-1586159
Entity Address, Address Line One	125 Broad Street
Entity Address, Address Line Two	Fifth Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02110
City Area Code	617
Local Phone Number	456-0597
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common stock, $0.0001 par value per share
Trading Symbol	AKLI
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 89,661,000	$ 76,899,000
Restricted cash	305,000	305,000
Short-term investments	66,696,000
Accounts receivable	30,000	29,000
Prepaid expenses and other current assets	4,586,000	2,500,000
Total current assets	161,278,000	79,733,000
Property and equipment, net	996,000	1,193,000
Operating lease right-of-use asset	2,760,000
Prepaid expenses and other long-term assets		11,000
Total assets	165,034,000	80,937,000
Current liabilities:
Accounts payable	3,486,000	2,345,000
Accrued expenses and other current liabilities	6,240,000	5,477,000
Deferred revenue	109,000	96,000
Deferred rent, short term	2,000	123,000
Current operating lease liability	803,000
Note payable, short term	2,500,000
Total current liabilities	13,140,000	8,041,000
Note payable, long term	12,436,000	4,784,000
Non-current operating lease liability	2,701,000
Corporate bond, net of bond discount	1,785,000	1,638,000
Earn-out liabilities	11,100,000
Deferred rent, long term		712,000
Total liabilities	41,162,000	15,175,000
Commitments and contingencies
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, $0.0001 par value: 100,000,000 and 48,102,729 shares authorized at September 30, 2022 and December 31, 2021, respectively; 0 and 43,318,218 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively		291,876,000
Stockholders' equity (deficit):
Common stock, $0.0001 par value: 1,000,000,000 and 63,315,481 shares authorized at September 30, 2022 and December 31, 2021, respectively; 77,858,746 and 1,674,106 share issued and outstanding at September 30, 2022 and December 31, 2021, respectively	8,000
Additional paid-in capital	347,330,000
Accumulated deficit	(223,473,000)	(226,114,000)
Accumulated other comprehensive gain	7,000
Total stockholders' equity (deficit)	123,872,000	(226,114,000)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$ 165,034,000	$ 80,937,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Aug. 18, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Redeemable convertible preferred stock, par value	$ 0.0001		$ 0.0001
Redeemable convertible preferred stock, shares authorized	100,000,000	48,102,729	48,102,729
Redeemable convertible preferred stock, shares issued	0	43,318,218	43,318,218
Redeemable convertible preferred stock, shares outstanding	0	43,318,218	43,318,218
Common stock, par value	$ 0.0001		$ 0.0001
Common stock, shares authorized	1,000,000,000		63,315,481
Common stock, shares issued	77,858,746		1,674,106
Common stock, shares outstanding	77,858,746		1,674,106

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 82,000	$ 155,000	$ 212,000	$ 377,000
Cost of revenues	123,000	83,000	316,000	243,000
Gross profit (loss)	(41,000)	72,000	(104,000)	134,000
Operating expenses:
Research and development	7,554,000	4,756,000	21,216,000	12,739,000
Selling, general and administrative	16,911,000	13,292,000	47,250,000	28,675,000
Total operating expenses	24,465,000	18,048,000	68,466,000	41,414,000
Operating loss	(24,506,000)	(17,976,000)	(68,570,000)	(41,280,000)
Other income (expense):
Other income	346,000	11,000	395,000	16,000
Interest expense	(496,000)	(172,000)	(866,000)	(292,000)
Extinguishment of debt				(181,000)
Change in estimated fair value of earn-out liabilities	77,892,000		77,892,000
Total other income (expense)	77,742,000	(161,000)	77,421,000	(457,000)
Income (loss) before income taxes	53,236,000	(18,137,000)	8,851,000	(41,737,000)
Income tax expense	0	0	0	0
Net income (loss)	53,236,000	(18,137,000)	8,851,000	(41,737,000)
Unrealized gain on short-term investments	14,000		7,000
Comprehensive income (loss)	53,250,000	(18,137,000)	8,858,000	(41,737,000)
Net income (loss)	53,236,000	(18,137,000)	8,851,000	(41,737,000)
Dividends on Series D convertible preferred stock	(1,598,000)	(2,773,000)	(7,383,000)	(3,888,000)
Redemption value of Series D convertible preferred stock	(799,000)	(1,386,000)	(3,692,000)	(57,263,000)
Net income (loss) per share attributable to common stockholders - basic	50,839,000	(22,296,000)	(2,224,000)	(102,888,000)
Net income (loss) attributable to common stockholders - diluted	$ 53,236,000	$ (22,296,000)	$ (2,224,000)	$ (102,888,000)
Net income (loss) per share attributable to common stockholders - basic	$ 1.38	$ (16.67)	$ (0.16)	$ (77.09)
Net income (loss) per share attributable to common stockholders - diluted	$ 0.76	$ (16.67)	$ (0.16)	$ (77.09)
Weighted average common stock outstanding - basic	36,920,116	1,337,797	13,690,186	1,334,562
Weighted average common shares outstanding - diluted	69,830,970	1,337,797	13,690,186	1,334,562

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (unaudited) - USD ($) $ in Thousands	Total	Adjusted balance	Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Adjusted balance	Common Stock	Common Stock Adjusted balance	Additional Paid-in Capital	Additional Paid-in Capital Adjusted balance	Accumulated Deficit	Accumulated Deficit Adjusted balance	Accumulated Other Comprehensive (Loss) Income
Beginning Balance at Dec. 31, 2020	$ (104,902)	$ (104,902)					$ 9,905	$ 9,905	$ (114,807)	$ (114,807)
Temporary Equity, Beginning Balance, Shares at Dec. 31, 2020			23,785,202	27,381,299
Temporary Equity, Beginning Balance at Dec. 31, 2020			$ 116,886	$ 116,886
Beginning Balance, Shares at Dec. 31, 2020					1,157,868	1,332,926
Retroactive application of recapitalization (Note 1)					175,058
Retroactive application of recapitalization (Note 1), Shares, Temporary Equity					3,596,097
Stock-based compensation expense	1,800						1,800
Exercise of stock options, Shares					6
Issuance of common stock warrants	268						268
Issuance of convertible preferred stock, net of issuance costs			$ 109,681
Issuance of convertible preferred stock, net of issuance costs, Shares			15,027,075
Stock dividend accrued for Series D preferred stock	(1,115)						(1,115)
Stock dividend accrued for Series D preferred stock, Temporary Equity			$ 1,115
Redemption value of Series D preferred stock	(55,877)						(10,858)		(45,019)
Redemption value of Series D preferred stock, Temporary Equity			$ 55,877
Net income (loss)	(23,600)								(23,600)
Ending Balance at Jun. 30, 2021	(183,426)								(183,426)
Temporary Equity, Ending Balance, Shares at Jun. 30, 2021			42,408,374
Temporary Equity, Ending Balance at Jun. 30, 2021			$ 283,559
Ending Balance, Shares at Jun. 30, 2021					1,332,932
Beginning Balance at Dec. 31, 2020	(104,902)	(104,902)					9,905	$ 9,905	(114,807)	(114,807)
Temporary Equity, Beginning Balance, Shares at Dec. 31, 2020			23,785,202	27,381,299
Temporary Equity, Beginning Balance at Dec. 31, 2020			$ 116,886	$ 116,886
Beginning Balance, Shares at Dec. 31, 2020					1,157,868	1,332,926
Net income (loss)	(41,737)
Ending Balance at Sep. 30, 2021	(203,828)								(203,828)
Temporary Equity, Ending Balance, Shares at Sep. 30, 2021			42,408,374
Temporary Equity, Ending Balance at Sep. 30, 2021			$ 287,718
Ending Balance, Shares at Sep. 30, 2021					1,456,530
Beginning Balance at Jun. 30, 2021	(183,426)								(183,426)
Temporary Equity, Beginning Balance, Shares at Jun. 30, 2021			42,408,374
Temporary Equity, Beginning Balance at Jun. 30, 2021			$ 283,559
Beginning Balance, Shares at Jun. 30, 2021					1,332,932
Stock-based compensation expense	1,748						1,748
Exercise of stock options	146						146
Exercise of stock options, Shares					123,599
Stock dividend accrued for Series D preferred stock	(2,773)						(1,510)		(1,263)
Stock dividend accrued for Series D preferred stock, Temporary Equity			2,773
Redemption value of Series D preferred stock	(1,386)						(384)		(1,002)
Redemption value of Series D preferred stock, Temporary Equity			$ 1,386
Net income (loss)	(18,137)								(18,137)
Ending Balance at Sep. 30, 2021	(203,828)								(203,828)
Temporary Equity, Ending Balance, Shares at Sep. 30, 2021			42,408,374
Temporary Equity, Ending Balance at Sep. 30, 2021			$ 287,718
Ending Balance, Shares at Sep. 30, 2021					1,456,530
Beginning Balance at Dec. 31, 2021	$ (226,114)	(226,114)							(226,114)	(226,114)
Temporary Equity, Beginning Balance, Shares at Dec. 31, 2021	43,318,218		37,629,060	43,318,218
Temporary Equity, Beginning Balance at Dec. 31, 2021	$ 291,876		$ 291,876	$ 291,876
Beginning Balance, Shares at Dec. 31, 2021					1,454,239	1,674,106
Retroactive application of recapitalization (Note 1)					219,867
Retroactive application of recapitalization (Note 1), Shares, Temporary Equity			5,689,158
Stock-based compensation expense	4,039						4,039
Exercise of stock options	105						105
Exercise of stock options, Shares					32,557
Stock dividend accrued for Series D preferred stock	(5,785)						(4,144)		(1,641)
Stock dividend accrued for Series D preferred stock, Temporary Equity			$ 5,785
Redemption value of Series D preferred stock	(2,893)								(2,893)
Redemption value of Series D preferred stock, Temporary Equity			$ 2,893
Other comprehensive gain (loss)	(7)										$ (7)
Net income (loss)	(44,385)								(44,385)
Ending Balance at Jun. 30, 2022	(275,040)								(275,033)		(7)
Temporary Equity, Ending Balance, Shares at Jun. 30, 2022			43,318,218
Temporary Equity, Ending Balance at Jun. 30, 2022			$ 300,554
Ending Balance, Shares at Jun. 30, 2022					1,706,663
Beginning Balance at Dec. 31, 2021	$ (226,114)	$ (226,114)							(226,114)	$ (226,114)
Temporary Equity, Beginning Balance, Shares at Dec. 31, 2021	43,318,218		37,629,060	43,318,218
Temporary Equity, Beginning Balance at Dec. 31, 2021	$ 291,876		$ 291,876	$ 291,876
Beginning Balance, Shares at Dec. 31, 2021					1,454,239	1,674,106
Exercise of stock options, Shares	58,745
Net income (loss)	$ 8,851
Ending Balance at Sep. 30, 2022	$ 123,872				$ 8		347,330		(223,473)		7
Temporary Equity, Ending Balance, Shares at Sep. 30, 2022	0
Ending Balance, Shares at Sep. 30, 2022					77,858,746
Beginning Balance at Jun. 30, 2022	$ (275,040)								(275,033)		(7)
Temporary Equity, Beginning Balance, Shares at Jun. 30, 2022			43,318,218
Temporary Equity, Beginning Balance at Jun. 30, 2022			$ 300,554
Beginning Balance, Shares at Jun. 30, 2022					1,706,663
Stock-based compensation expense	1,673						1,673
Exercise of stock options	40						40
Exercise of stock options, Shares					26,188
Stock dividend accrued for Series D preferred stock	(1,598)						(721)		(877)
Stock dividend accrued for Series D preferred stock, Temporary Equity			$ 1,598
Stock dividend accrued for Series D preferred stock, Shares, Temporary Equity			1,008,596
Redemption value of Series D preferred stock	(799)								(799)
Redemption value of Series D preferred stock, Temporary Equity			$ 799
Redemption value of Series D preferred stock, Shares, Temporary Equity			8,472,752
Exercise of Legacy Akili warrants					8,834
Conversion of redeemable preferred stock into permanent equity, Temporary Equity			$ (302,951)
Conversion of redeemable preferred stock into permanent equity, Shares, Temporary Equity			(52,799,566)
Conversion of redeemable preferred stock into permanent equity	302,951				$ 5		302,946
Conversion of redeemable preferred stock into permanent equity, Shares					52,799,566
Issuance of common stock upon Business Combination and PIPE Investment	164,283				$ 3		164,280
Issuance of common stock upon Business Combination and PIPE Investment, Shares					23,317,495
Reverse recapitalization, net of transaction costs (including ($87,512) of deemed dividends related to Earn-Out Shareholders)	(120,888)						(120,888)
Other comprehensive gain (loss)	14										14
Net income (loss)	53,236								53,236
Ending Balance at Sep. 30, 2022	$ 123,872				$ 8		$ 347,330		$ (223,473)		$ 7
Temporary Equity, Ending Balance, Shares at Sep. 30, 2022	0
Ending Balance, Shares at Sep. 30, 2022					77,858,746

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) (unaudited) $ in Thousands	3 Months Ended
	Sep. 30, 2022 USD ($)
Earn-Out Shareholders
Deemed dividends	$ 87,512

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net income (loss)	$ 8,851	$ (41,737)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	231	198
Reduction in the carrying amount of right-of-use assets	362
Stock-based compensation expense	7,192	3,548
Loss on extinguishment of debt		181
Loss on disposal of fixed assets		13
Amortization of premium on short-term investments	(97)
Non Cash Interest Expense	299	135
Change in fair value of earn-out liabilities	(77,892)
Changes in operating assets and liabilities:
Accounts receivable	(1)	(21)
Prepaid expenses and other current assets	(2,086)	(1,126)
Prepaid expenses and other long-term assets	11	(84)
Accounts payable	1,193	786
Accrued expenses and other current liabilities	(187)	2,457
Deferred rent	(20)	(86)
Operating lease liabilities	(431)
Deferred revenue	13	(197)
Net cash used in operating activities	(62,562)	(35,933)
Cash flows from investing activities:
Acquisition of property and equipment	(42)	(53)
Capitalized software development costs		(427)
Purchases of short-term investments	(81,593)
Proceeds from maturities of short-term investments	15,000
Net cash used in investing activities	(66,635)	(480)
Cash flows from financing activities:
Proceeds from exercise of stock options	145	146
Proceeds from note payable	10,000	5,000
Proceeds from issuance of preferred stock, net issuance costs		109,681
Proceeds from business combination net of transaction costs paid	131,814
Payment of debt issuance costs		(74)
Payment of premium on note payable		(26)
Repayment of principal on note payable		(2,000)
Net cash provided by financing activities	141,959	112,727
Net increase (decrease) in cash, cash equivalents, and restricted cash	12,762	76,314
Cash, cash equivalents, and restricted cash at beginning of period	77,204	18,833
Cash, cash equivalents, and restricted cash at end of period	89,966	95,147
Supplementary Information:
Cash paid for interest	453	128
Noncash investing and financing activities:
Purchase of property and equipment included in accounts payable and accrued expenses		11
Common stock warrants issued related to note payable		268
Redemption value of Series D preferred stock	3,692	57,263
Dividends accrued for Series D preferred stock	7,383	$ 3,888
Recognition of earn-out liabilities	87,512
Net liabilities assumed in the business combination	$ 950

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Busin ess and Basis of Presentation Organization Akili, Inc. (collectively referred to with its wholly-owned, controlled subsidiaries, as “Akili” or the “Company”) operates as one business segment and is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder (“ADHD”), major depressive disorder, autism spectrum disorder, multiple sclerosis, and various neuroinflammatory diseases. In June 2020, the U.S. Food and Drug Administration (“FDA”) granted clearance for EndeavorRx as a prescription treatment for children with ADHD. The Company is headquartered in Boston, Massachusetts. On August 19, 2022, (the “Closing Date”), Social Capital Suvretta Holdings Corp. I, (“SCS”) consummated the previously announced merger pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 26, 2022, by and among SCS, Akili Interactive Labs, Inc. and Karibu Merger Sub, Inc., pursuant to which Karibu Merger Sub, Inc. merged with and into Akili Interactive Labs, Inc., with Akili Interactive Labs, Inc. becoming a wholly owned subsidiary of SCS (the “Business Combination”). Upon the closing of the Business Combination (the "Closing"), SCS changed its name to Akili, Inc. In connection with the Business Combination, SCS completed the sale and issuance of 16,200,000 shares of Akili, Inc. common stock, $ 0.0001 par value per share (the "Common Stock") in a private placement transaction for a purchase price of $ 10.00 per share for $ 162,000 in the aggregate (the “PIPE Investment”). Gross proceeds from the Merger totaled approximately $ 164,283 which included funds held in SCS’s trust account (after giving effect to redemptions). In connection with the Business Combination, approximately $ 31,438 of transaction costs and other fees were incurred. References to SCS refer to the Company prior to the consummation of the Business Combination and references to “Legacy Akili” refer to Akili Interactive Labs, Inc. (now a wholly-owned subsidiary of Akili, Inc.) prior to the consummation of the Business Combination. Legacy Akili was deemed the accounting acquirer in the Business Combination. This determination was primarily based on Legacy Akili’s stockholders prior to the Business Combination having a majority of the voting power in the combined company, Legacy Akili having the ability to appoint a majority of the board of directors of the combined company (the "Board"), Legacy Akili’s existing management comprising the senior management of the combined company, Legacy Akili comprising the ongoing operations of the combined company, Legacy Akili being the larger entity based on historical revenues and business operations, and the combined company assuming Legacy Akili’s name. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy Akili issuing stock for the net assets of SCS, accompanied by a recapitalization. Under this method of accounting, SCS who was the legal acquirer, is treated as the “acquired” company for financial reporting purposes. The net assets of SCS are stated at historical cost, with no goodwill or other intangible assets recorded. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s Common Stock, $ 0.0001 par value per share, issued to Legacy Akili stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Akili’s convertible preferred stock (“Legacy Convertible Preferred Stock”) and Legacy Akili common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 1.15 pursuant to the terms of the Business Combination. Legacy Convertible Preferred Stock previously classified as mezzanine was retroactively adjusted, converted into Common Stock, and reclassified to permanent as a result of the reverse recapitalization. See Note 10 for more information. Akili, Inc. (formerly SCS) is a Delaware corporation incorporated on December 1, 2020. Akili Interactive Labs, Inc. is a Delaware corporation incorporated on December 1, 2011. Going Concern The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance- reporting capabilities. Most of the Company’s product candidates are still in development. There can be no assurance that the Company’s research and development will be successfully completed; that adequate protection for the Company’s intellectual property will be obtained; that any products developed will obtain necessary government regulatory approval; or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative operating cash flows for the nine months ended September 30, 2022 and had an accumulated deficit of $ 223,473 . The Company believes that its cash and cash equivalents and short-term investments at September 30, 2022 of $ 156,357 , along with the $ 15,000 available undrawn debt, will be sufficient to fund the Company’s planned operations and existing obligations for at least one year after the date that the condensed consolidated financial statements are issued. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company’s failure to raise capital when needed, or on terms favorable to the Company, could have a negative impact on its financial condition and ability to pursue its business strategies. COVID-19 Related Significant Risks and Uncertainties There continue to be uncertainties regarding the pandemic of the novel coronavirus ("COVID-19") and the Company is closely monitoring the impact of COVID-19 on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, and business partners. The Company is unable to predict the specific impact that COVID-19 may have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein may change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-19. In response to the COVID-19 pandemic, Congress passed the Coronavirus Aid, Relief and Economic Security Act of 2020 (the "CARES Act") which was signed into law on March 27, 2020. The CARES Act provides for deferred payment of the employer portion of social security taxes through the end of 2020, with a portion of the deferred amount due by December 31, 2022. As of September 30, 2022 and December 31, 2021, the Company has deferred payments of $ 187 of social security taxes, which is included in accrued expenses and other current liabilities within the condensed consolidated balance sheet. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company, after elimination of all intercompany accounts and transactions. As permitted for interim reporting, certain footnotes or other financial information that are normally required by U.S. GAAP may be condensed or omitted, unless otherwise required by U.S. GAAP or Securities and Exchange Commission (“SEC”) rules and regulations. These condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with the Company’s annual consolidated financial statements included in the Company's final prospectus filed pursuant to Rule 424(b)(3) under the Securities Act with the SEC on October 17, 2022. In the opinion of management, all adjustments of a normal recurring nature, considered necessary for fair presentation, have been included in these condensed consolidated financial statements. The results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or future year. The condensed consolidated balance sheet as of December 31, 2021 was derived from the audited annual consolidated financial statements but does not include all information required by U.S. GAAP for annual consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021, included in the Company's final prospectus filed pursuant to Rule 424(b)(3) under the Securities Act with the SEC on October 17, 2022. Since the date of those consolidated financial statements, there have been no changes to the Company’s significant accounting policies except as noted below. Legacy Convertible Preferred Stock: In connection with the Business Combination, all Legacy Convertible Preferred Stock were converted to common stock of Legacy Akili. See Notes 1, 3, and 10 for further information. The Company recorded shares of Legacy Convertible Preferred Stock at their respective estimated fair values on the dates of issuance, net of issuance costs. Legacy Convertible Preferred Stock was classified outside of stockholders’ deficit because the holders of such shares had liquidation and redemption rights in the event of a deemed liquidation event that, in certain situations, are not solely within the control of the Company, such as a merger, acquisition, and sale of all or substantially all of the Company’s assets. Earn-Out Liabilities: In connection with the Business Combination, holders of Legacy Akili common stock, Legacy Convertible Preferred Stock and warrants to purchase shares of Legacy Akili common stock ("Earn-Out Shareholders") and employees or individual service providers holding options to purchase shares of Legacy Akili common stock, in each case as designated by the Board of Akili as an earn-out service provider prior to the Closing Date (“Earn-Out Service Providers”) received the contingent right to receive additional Common Stock upon the achievement of certain earn-out targets (the “Rights”). The Company concluded the issuance of Rights to Earn-Out Shareholders constitutes a deemed dividend and evaluated the Rights for classification under guidance applicable to financial instruments. In assessing classification, the Company considered ASC Subtopic 815-40 “ Contracts in Entity’s Own Equity ” and determined the Rights contain settlement provisions that preclude them from being indexed to the Company’s stock and accordingly liability classification is required. The Company concluded issuance of the Rights to Earn-Out Service Providers represents compensation in scope of ASC Topic 718, " Compensation - Stock Compensation. " In considering relevant classification guidance, the Company determined the Rights issued to Earn-Out Service Providers are liabilities because they are indexed to whether such Earn-Out Service Providers hold qualifying equity instruments when the earn-out targets are achieved. The fair value of the contingent earn-out consideration is estimated as of the Closing Date at the present value of the expected contingent earn-out consideration using a Monte Carlo Simulation Method ("MCSM"). The Company reviews the probability of achievement of the earn-out targets to determine the impact on the fair value of the earn-out consideration on a quarterly basis over the earn-out period. For Earn-Out Shareholders, the corresponding fair value was initially recorded against additional paid-in capital. Changes in the estimated fair value of the contingent earn-out consideration related to Earn-Out Shareholders are recorded in other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) and are reflected in the period in which they are identified. For Earn-Out Service Providers, the corresponding fair value was initially recorded within operating expenses in the same functional category as the grantees' operating expenses. Changes in the estimated fair value of contingent earn-out consideration related to Earn-Out Service Providers is recorded as stock compensation for the period. Changes in the estimated fair value of the contingent earn-out consideration may materially impact or cause volatility in the Company's operating results. Transaction Costs: The Company has allocated certain transaction costs to the Earn-out Shares based on the relative fair value of these instruments as compared to the other newly issued instruments as part of the Business Combination. The portion of transaction costs allocated to these instruments is reflected as a reduction to cash and an increase in selling, general and administrative expense. The costs were determined to relate to future share issuances and not to the initial recapitalization and therefore they were expensed on the Closing Date. All costs allocated to the other newly issued instruments, which consisted of Common Stock, were recorded in total permanent equity (deficit) as a reduction of additional paid-in capital. Investments: The Company considers all investments with original maturities of more than three months but less than one year to be short-term investments. All investments in marketable securities are classified as available for sale. Available-for-sale securities are reported at fair value, with temporary unrealized gains and losses excluded from earnings and reported as a separate component of stockholders’ equity, while other-than-temporary gains or losses are included in earnings. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the condensed consolidated statements of operations and comprehensive income (loss). Revenue: The following table presents the Company’s revenue by type: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Product revenue $ 82 $ 57 $ 212 $ 123 Collaboration revenue - 98 - 254 Total $ 82 $ 155 $ 212 $ 377 As of September 30, 2022, the Company has a contract liability related to product revenue, which consists of amounts that have been paid but have not been recognized as revenue. All amounts are expected to be recognized as revenue within 12 months of the balance sheet date and are classified as current deferred revenue. The Company recognized $ 72 of product revenue in the nine months ended September 30, 2022 that was previously included in the December 31, 2021 deferred revenue balance. Contract Liabilities Product Balance at December 31, 2021 $ 96 Revenue recognized ( 212 ) Revenue deferred 225 Balance at September 30, 2022 $ 109 Advertising: The Company expenses advertising costs as incurred. Advertising expenses were $ 464 and $ 6,401 during the three and nine months ended September 30, 2022. Advertising expenses were $ 4,893 and $ 7,760 during the three and nine months ended September 30, 2021 . Leases: The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since it does not currently have a rating agency-based credit rating. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. The Company has elected the practical expedient not to separate lease and non-lease components for real estate leases. Recently adopted accounting pronouncements: In February 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”), Leases (Topic 842) as amended by ASU 2019-10 and ASU 2020-05, which supersedes the guidance in former ASC Topic 840, Leases . The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less are not impacted by the new guidance. The Company adopted this guidance, effective January 1, 2022 , using the modified retrospective method as of the date of adoption such that prior periods will not be restated. The Company elected a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. Additional disclosures related to accounting for leases under this new standard are included in Note 5. The adoption incrementally increased the Company’s assets and liabilities by the right-of-use asset and lease liabilities. As the leases do not provide an implicit rate, the Company’s incremental borrowing rate was determined based on the information available at the date of adoption to measure its lease liability. The adoption did not have a material impact on the Company’s condensed consolidated statement of operations and comprehensive income (loss) and did not require a cumulative adjustment to accumulated deficit on its condensed consolidated statement of stockholders’ equity as of September 30, 2022. Recently issued accounting pronouncements: In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), as amended by ASU 2019-10. ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. ASU 2016-13 is effective for the Company for the annual reporting period beginning January 1, 2023. The Company is currently evaluating the potential impact this standard may have on its consolidated financial statements and results of operations. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes-Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This standard is effective for annual reporting periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. The Company is currently evaluating the potential impact that ASU 2019-12 will have on its consolidated financial statements and related disclosures; however, it does not expect the impact to be material.

Business Combination

Business Combination	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Business Combination	3. Business Combination As discussed in Note 1, on August 19, 2022, the Company consummated the Business Combination pursuant to the Merger Agreement. The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, SCS, who was the legal acquirer, was treated as the “acquired” company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Akili issuing stock for the net assets of SCS, accompanied by a recapitalization. Upon the Closing, holders of Legacy Akili common stock received shares of Common Stock in an amount determined by application of the exchange ratio of approximately 1.15 (the “Exchange Ratio”), which was based on Legacy Akili’s implied price per share prior to the Business Combination. For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities and results of operations prior to the Business Combination are those of Legacy Akili. In connection with the Business Combination, approximately $ 31,438 of transaction related expenses and other costs were incurred. The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: Nine months ended September 30, 2022 Cash - SCS trust and cash (net of redemptions) $ 2,283 Cash - PIPE investors 162,000 Gross proceeds 164,283 Transaction related expenses and other costs paid at Closing (of which $ 8,850 represent the Company's transaction costs) ( 30,989 ) Transaction related expenses and other costs paid after Closing ( 449 ) Net proceeds from the Business Combination 132,845 In addition to the $ 8,850 paid at Closing noted in the table above, the Company incurred $ 4,077 in additional transaction costs related to certain legal, accounting, consulting and other third-party fees incurred. These transaction costs were incurred and paid during the nine months ended September 30, 2022. Of the Company's total transaction costs of $ 12,927 , $ 3,046 was allocated to the Earn-Out Shares and expensed upon the Closing, based on the relative fair value of the Earn-Out Shares as compared to the other newly issued instruments as part of the Business Combination. The remaining Company transaction costs were recorded in additional paid-in capital. The number of shares of Common Stock outstanding immediately following the Closing was as follows: Common Stock SCS public stockholders 227,522 SCS sponsor and independent director 6,890,000 Legacy Akili stockholders (1) 54,541,224 PIPE investors 16,200,000 Total shares of Common Stock immediately after Closing 77,858,746 (1) The number of Legacy Akili shares was determined from the shares of Legacy Akili shares outstanding immediately prior to the Closing converted at the Exchange Ratio of approximately 1.15 . The amount includes the cashless exercise of certain outstanding Akili Interactive Labs, Inc. warrants, which resulted in the issuance of 8,834 shares of Common Stock. All fractional shares were rounded down. Amount excludes the issuance of 7,536,461 Earn-Out Shares (as defined below), as the performance conditions have not yet been satisfied. Earn-Out Shares: Earn-Out Shareholders and Earn-Out Service Providers received the contingent right to receive additional shares of Common Stock upon the achievement of certain earn-out targets. Earn-Out Shareholders and Earn-Out Service Providers are eligible to receive up to 7,536,461 shares in the aggregate (the "Earn-Out" Shares) of additional Common Stock in three equal tranches upon the Company achieving $ 15.00 , $ 20.00 , or $ 30.00 , respectively, as its volume-weighted average price per share of Common Stock for any 20 trading days within a 30 consecutive trading day period (as adjusted for share splits, reverse share splits, share dividends, reorganizations, recapitalizations, reclassifications, combination, exchange of shares, or the like). As the Earn-Out Shares to Earn-Out Shareholders contain a settlement provision that precludes them from being indexed to the Company’s stock under ASC 815, Derivatives and Hedging , they are classified as liabilities. The Company accounts for the potential issuance of the Earn-Out Shares to Earn-Out Shareholders as a contingent consideration arrangement, a liability for which was initially valued and recorded using a MCSM for each earn-out period. Key inputs and assumptions were the Company’s stock price, expected term, volatility, the risk-free rate, and dividend yield. Some of these inputs are Level 3 assumptions that are updated each reporting period as the earn-out liabilities are recorded at fair value on a recurring basis. The Company revalued the earn-out liabilities as of September 30, 2022 and the change in the fair value of the earn-out liabilities was recorded in other income (expense) on the statement of operations. As the Earn-Out Shares to Earn-Out Service Providers are indexed to whether such Earn-Out Service Providers hold qualifying equity instruments when the earn-out targets are achieved, they are classified as a liability under ASC 718, " Compensation-Stock Compensation ". The Company accounts for the potential issuance of the Earn-Out Shares to Earn-Out Service Providers as the grant of a compensatory award under ASC 718. As there are no continuing service obligations, the awards were expensed on the date of the Business Combination and the fair value is updated each reporting period. The change in fair value is recorded as stock compensation for the period in the same functional category as the grantees' operating expenses. Earn-Out Shareholders Earn-Out Service Providers Total Fair value as of December 31, 2021 $ - $ - $ - Initial fair value of earn-out liabilities at date of Business Combination 87,512 13,467 100,979 Change in fair value ( 77,892 ) ( 11,987 ) ( 89,879 ) Fair value as of September 30, 2022 $ 9,620 $ 1,480 $ 11,100

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2022
Prepaid Expense Current [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: September 30, December 31, Deferred issuance costs $ - $ 572 Prepaid clinical trials 829 872 Prepaid insurance 2,107 81 Other current assets 1,650 975 Prepaid expenses and other current assets $ 4,586 $ 2,500

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2022
Property Plant And Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment, net consisted of the following: September 30, December 31, Furniture and fixtures $ 184 $ 184 Computer equipment and software 477 443 Office equipment 60 60 Leasehold improvements 975 975 Capitalized internal-use software costs 427 427 Total property and equipment 2,123 2,089 Less: accumulated depreciation and amortization ( 1,127 ) ( 896 ) Property and equipment, net $ 996 $ 1,193 Depreciation and amortization expense was $ 77 and $ 231 for the three and nine months ended September 30, 2022. Depreciation and amortization expense was $ 60 and $ 198 for the three and nine months ended September 30, 2021 .

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	6. Leases As of September 30, 2022 , the Company leases office space under non-cancelable operating leases in two cities. The lease for office space in Boston, Massachusetts was amended in September 2022 to extend the rental of one floor consisting of approximately 4,000 square feet, which will expire in December 2023 . In accordance with ASC 842, “ Leases", as the lease term is greater than one year, it is recognized on the balance sheet as right-of-use assets and lease liabilities. The office space in Larkspur, California consists of approximately 43,600 square feet pursuant to a lease that will expire in November 2026 . The Company provided a customary letter of credit in the amount of approximately $ 250 as a security deposit, which is included in restricted cash within the condensed consolidated balance sheets. These leases do not include any restrictions or covenants that had to be accounted for under the new lease guidance. During the three and nine months ended September 30, 2022, the Company recognized $ 262 and $ 786 of rent expense. During the three and nine months ended September 30, 2021, the Company recognized $ 269 and $ 854 of rent expense. Net cash paid for the amounts included in the measurement of the operating lease liability on the condensed consolidated balance sheet and operating activities in the condensed consolidated statement of cash flow was $ 630 for the nine months ended September 30, 2022. The weighted average remaining lease term and incremental borrowing rate as of September 30, 2022 was 4.0 years and 7.5 % , respectively. Future lease payments for our noncancelable operating leases as of September 30, 2022 and a reconciliation to the carrying amount of the operating lease liability presented in the condensed consolidated balance sheet as of September 30, 2022 is as follows: Years Ending December 31, Amounts 2022 (remaining 3 months) $ 256 2023 1,042 2024 914 2025 950 2026 905 Total undiscounted payments due under operating leases 4,067 Less imputed interest ( 563 ) Total $ 3,504 Current operating lease liability $ 803 Non-current operating lease liability 2,701 Total $ 3,504 For comparable purposes, aggregate future minimum non-cancellable commitments under leases as of December 31, 2021, are as follows: Years Ending December 31, Amounts 2022 (remaining 3 months) $ 242 2023 878 2024 914 2025 950 2026 905 Total $ 3,889

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: September 30, December 31, Accrued bonus $ 2,592 $ 2,516 Accrued royalties 105 106 Accrued wages and benefits 714 421 Accrued clinical study expenses 416 363 Accrued consulting service expenses 702 766 Other accrued expenses 1,711 1,305 Total $ 6,240 $ 5,477

Corporate Bond

Corporate Bond	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Corporate Bond	8. Corporate Bond In March 2019, in connection with Shionogi & Co., Ltd exercising its option to enter into a collaboration agreement with the Company, the Company issued a $ 5,000 corporate bond to Shionogi for cash (the “Corporate Bond”). The Corporate Bond is unsecured and is subordinated to the obligations of the Company under indebtedness for borrowed money owed by the Company to any bank or other financial institution. The Company recognized amortization expense of $ 50 and $ 147 related to the discount on the Corporate Bond as a component of interest expense in the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2022. The Company recognized amortization expense of $ 44 and $ 131 for the three and nine months ended September 30, 2021. The carrying amount of the corporate bond is as follows: September 30, December 31, Corporate Bond $ 5,000 $ 5,000 Unamortized discount on Corporate Bond ( 3,215 ) ( 3,362 ) Corporate Bond, net of discount $ 1,785 $ 1,638

Note Payable

Note Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Note Payable	9. Note Payable Amended and Restated Loan and Security Agreement On June 28, 2022, the Company drew an additional $ 10,000 from Tranche 1 of the Amended and Restated Loan and Security Agreement with Silicon Valley Bank. The Company is required to make interest-only payments through May 2023 before beginning to repay the $ 15,000 in outstanding principal in 24 equal monthly payments on the first day of each month beginning June 1, 2023, plus interest. In relation to this additional draw of $ 10,000 , the Company incurred $ 500 of debt issuance costs in the form of a final payment fee. At September 30, 2022 , the Company had outstanding principal of $ 15,000 . The Company recognized interest expense related to debt issuance costs of $ 178 for the nine months ended September 30, 2022. The interest rate in effect as of September 30, 2022 was 10.0 % . At September 30, 2022 , the carrying amount of the note payable (excluding the current portion of $ 2,500 ) is as follows: Outstanding principal $ 15,000 Note payable, short term ( 2,500 ) Final Payment 750 Unamortized debt issuance costs ( 814 ) Note payable, long term (net of debt issuance costs) $ 12,436 Future minimum principal payments due under the Amended and Restated Loan and Security Agreement, excluding the Final Payment, are as follows: Years Ending December 31, Remainder of 2022 $ - 2023 4,375 2024 7,500 2025 3,125 Total $ 15,000

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Capital Stock	10. Capital Stock The Company's authorized capital stock consists of 1,000,000,000 shares of Common Stock, par value $ 0.0001 per share and 100,000,000 shares of preferred stock, par value $ 0.0001 per share . As of September 30, 2022, there were 77,858,746 shares of Common Stock issued and outstanding and 242,924 warrants outstanding to purchase Common Stock. There were no shares of preferred stock issued and outstanding. The holders of the Common Stock are entitled to one vote for each share of Common Stock. The holders of Common Stock shall be entitled to receive dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Common Stock shall be entitled to share ratably in the remaining assets of the Company available for distribution. The Board or any authorized committee thereof is authorized to issue shares of preferred stock and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the relative, participating, optional or other special rights of the shares of each series and any qualifications, limitations and restrictions thereof. Legacy Convertible Preferred Stock In connection with the Business Combination, the Legacy Convertible Preferred Stock was retroactively adjusted, converted into Common Stock, and reclassified to permanent equity as a result of the reverse recapitalization. As of September 30, 2022, there is no Legacy Convertible Preferred Stock authorized, issued or outstanding. The following table summarizes details of Legacy Convertible Preferred Stock authorized, issued and outstanding on the Closing Date immediately prior to the Business Combination: Legacy Convertible Preferred Series Par Value Authorized (1) Issued and Outstanding (1) Carrying Value (2) Series A-1 Convertible Preferred Stock $ 0.0001 4,604,762 4,604,762 $ — Series A-2 Convertible Preferred Stock 0.0001 5,096,403 5,096,403 7,128 Series B Convertible Preferred Stock 0.0001 8,451,448 8,451,448 41,854 Series C Convertible Preferred Stock 0.0001 9,228,686 9,228,686 67,904 Series D Convertible Preferred Stock 0.0001 20,721,430 15,936,919 186,065 Total 48,102,729 43,318,218 $ 302,951 (1) Shares authorized, shares issued and outstanding, and the conversion price/share have been adjusted to reflect the exchange of Legacy Convertible Preferred Stock for Akili, Inc. Common Stock at an exchange ratio of approximately 1.15 as a result of the Business Combination. (2) For the purpose of this calculation, the Series D redeemable convertible preferred stock continued to accrue dividends through the Closing Date and the adjusted total of Series D redeemable convertible preferred stock was multiplied by 150 % to determine the carrying value on the date of the Business Combination. Conversion—The holders of Legacy Convertible Preferred Stock had the right, at their option at any time, to convert any shares of Legacy Convertible Preferred Stock into fully paid and nonassessable shares of Legacy Akili common stock. The conversion ratio is determined by dividing the original issue price by the conversion price, which is equal to $ 1.00 , $ 1.995 , $ 5.7699 , $ 8.5073 , and $ 8.426854 per share for the Legacy Akili Series A-1, A-2, B, C, and D preferred stock, respectively. Conversion was mandatory upon the closing of a merger, combination or transaction with a special purpose acquisition company resulting in at least $ 75,000 of gross proceeds to the Company . Employee Stock Purchase Plan In connection with the Closing, the Company adopted the 2022 Employee Stock Purchase Plan (the “2022 ESPP”). The 2022 ESPP is a shareholder-approved plan under which substantially all employees may voluntarily enroll to purchase the Company’s Common Stock through payroll deductions at a price equal to 85 % of the lower of the fair market values of the stock as of the offering date or the exercise date, provided that no offering shall exceed 27 months. An employee’s payroll deductions under the 2022 ESPP are limited to 15 % of the employee’s compensation and employees may not purchase more than $ 25,000 of stock during any calendar year. A total of 1,167,881 shares of our Common Stock are reserved and authorized for issuance under the 2022 ESPP. In addition, the number of shares of Common Stock available for issuance under the 2022 ESPP is automatically increased each January 1 of each calendar year beginning on January 1, 2023, and ending in 2031, by the least of (i) the excess (if any) of (A) 1 % of the outstanding shares issued and outstanding on the immediately preceding December 31st (excluding any shares reserved for issuance under equity-based plans of Akili, Inc. including the 2022 Stock Option and Incentive Plan and the 2022 ESPP) over (B) the number of shares of stock then reserved for issuance under the 2022 ESPP as of such date, (ii) 1,167,881 or (iii) such number of shares determined by the administrator. Through September 30, 2022, no shares have been issued under the 2022 ESPP.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation 2011 Stock Incentive Plan: Prior to the Business Combination, the Company’s 2011 Stock Incentive Plan (the “2011 Plan”) allowed the Company to grant incentive stock options, nonqualified stock options, and restricted stock to employees, directors, and nonemployees of the Company. Upon the Closing, the remaining unallocated share reserve under the 2011 Plan was cancelled and no new awards will be granted under such plan. Awards outstanding under the 2011 Plan were assumed by Akili, Inc. upon the Closing and continue to be governed by the terms of the 2011 Plan. 2022 Stock Option and Incentive Plan: In 2022, the Board approved the 2022 Stock Option and Incentive Plan, (the “2022 Plan”), which provides for the grant of incentive stock options, nonqualified stock options, and restricted stock to employees, directors, and nonemployees of the Company up to an aggregate of 12,813,781 shares of the Company’s Common Stock. All of these shares remain available for issuance under the 2022 Plan as of September 30, 2022. Options generally vest based on the grantee’s continued service with the Company during a specified period following a grant as determined by the Board and expire ten years from the grant date. Awards typically vest in four years , but vesting conditions can vary based on the discretion of the Board. Stock-based compensation expense, including the expense related to Earn-Out Service Providers, is classified in the condensed consolidated statements of operations and comprehensive income (loss) as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ 1,312 $ 408 $ 2,762 $ 920 Selling, general and administrative 1,841 1,340 4,430 2,628 Total $ 3,153 $ 1,748 $ 7,192 $ 3,548 Included in the three and nine months ended September 30, 2022 balances in the table above is $ 1,480 of stock-based compensation related to the potential issuance of the Earn-Out Shares to Earn-Out Service Providers, as described in Note 3. A summary of the Company’s stock option activity and related information is as follows: Number of Weighted- Weighted- Aggregate Balance at December 31, 2021 8,667,093 $ 3.38 7.28 Granted 1,536,102 $ 10.06 Cancelled ( 631,747 ) $ 3.94 Exercised ( 58,745 ) $ 2.49 Balance at September 30, 2022 9,512,703 $ 4.43 6.87 $ 1,052 Exercisable September 30, 2022 6,208,060 $ 3.34 5.86 $ 1,052 Options vested and expected to vest, September 30, 2022 9,512,703 $ 4.43 6.87 $ 1,052 The fair value of all option activity was estimated at the date of grant using a Black-Scholes model with the following weighted-average assumptions for the nine months ended September 30, 2022 and 2021: Nine Months Ended 2022 2021 Fair value of Common Stock $ 10.06 $ 4.40 Expected volatility 96.21 % 98.73 % Expected term (in years) 6.03 4.88 Risk-free interest rate 1.73 % 0.81 % Expected dividend yield 0.00 % 0.00 % The weighted average grant-date fair value of stock options granted to employees during the nine months ended September 30, 2022 and 2021 was $ 7.79 and $ 3.39 per share, respectively. During the nine months ended September 30, 2022 and 2021, the aggregate intrinsic value of stock option awards exercised was $ 445 and $ 327 , respectively. Aggregate intrinsic value represents the difference between the exercise price and the fair value of the underlying Common Stock on the date of exercise. As of September 30, 2022 there was $ 14,203 of unrecognized compensation cost related to unvested stock option grants to employees under the 2022 Plan, which is expected to be recognized over a weighted-average period of 2.9 years.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities	12. Fair Value of Financial Assets and Liabilities The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: Fair Value Measurements as of September 30, 2022 Description Level 1 Level 2 Level 3 Total Assets Cash equivalents: Money market funds $ 56,993 $ - $ - $ 56,993 Short-term investments: United States treasuries 66,696 - - 66,696 Total assets $ 123,689 $ - $ - $ 123,689 Long-term liabilities: Earn-out liabilities - - 11,100 11,100 Total liabilities $ - $ - $ 11,100 $ 11,100 Fair Value Measurements as of December 31, 2021 Description Level 1 Level 2 Level 3 Total Assets Cash equivalents: Money market funds $ 61,509 $ — $ — $ 61,509 The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the nine months ended September 30, 2022 and 2021. The Company recorded unrealized gains on short-term investments of $ 7 in other comprehensive gain for the nine months ended September 30, 2022. As of September 30, 2022 and December 31, 2021 , the Company’s cash equivalents consisted of money market funds with original maturities of less than 90 days from the date of purchase. As of September 30, 2022 , the Company’s short-term investments consisted of United States treasuries with original maturities of more than three months but less than one year . As of December 31, 2021 , the Company did no t have any liabilities that are measured at fair value on a recurring basis. Earn-out liabilities — Upon the Closing, the Earn-Out Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned (the "Triggering Events") included events that were indexed to the Common Stock of the Company, with the change in fair value recognized in "Change in estimated fair value of earn-out liabilities" in the condensed consolidated statement of operations. The estimated fair value of the Earn-out Shares was determined using a MCSM using the following assumptions at each valuation date: Price target : price target as defined in the Merger Agreement for each Triggering Event: • Triggering Event I is $ 15.00 per share • Triggering Event II is $ 20.00 per share • Triggering Event III is $ 30.00 per share Current stock price : the closing stock price as quoted on Nasdaq as of September 30, 2022 and Closing Date was $ 2.26 and $ 14.07 per share, respectively. Expected term : the expected term is the five-year term of the earn-out period. Expected volatility : the volatility rate as of September 30, 2022 and Closing Date was 97.5 % and 100.0 %, respectively. The volatility rate was determined using an average of historical volatilities over the expected term of selected industry peers deemed comparable to the Company. Expected dividend yield : the expected dividend yield is zero as it is not expected that the Company will declare dividends on Common Stock during the expected term. See Note 3 for a table that reconciles the change in fair value of the earn-out liabilities valued using Level 3 inputs.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	13. Net Income (Loss) Per Share The computation of basic net income (loss) per share is based on the weighted-average number of our common shares outstanding. The computation of diluted net income (loss) per share is based on the weighted-average number of our common shares outstanding and potential dilutive common shares during the period as determined by the treasury stock method. The following table summarizes the computation of basic and diluted net income (loss) per share attributable to common stockholders of the Company: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator: Net income (loss) attributable to common stockholders - basic $ 50,839 $ ( 22,296 ) $ ( 2,224 ) $ ( 102,888 ) Dividends on Series D convertible preferred stock 1,598 - - - Redemption value of Series D convertible preferred stock 799 - - - Net income (loss) attributable to common stockholders - diluted $ 53,236 $ ( 22,296 ) $ — $ ( 2,224 ) $ ( 102,888 ) Denominator: Weighted average Common Stock outstanding - basic 36,920,116 1,337,797 13,690,186 1,334,562 Weighted average effect of potentially dilutive securities: Effect of potentially dilutive convertible preferred stock 28,695,420 - - - Effect of potentially dilutive warrants 122,713 - - - Effect of potentially dilutive stock options 4,092,721 - - - Total potentially dilutive securities 32,910,854 - - - Weighted average common stock outstanding - diluted 69,830,970 1,337,797 13,690,186 1,334,562 Net income (loss) per share attributable to common stockholders - basic $ 1.38 $ ( 16.67 ) $ ( 0.16 ) $ ( 77.09 ) Net income (loss) per share attributable to common stockholders - diluted $ 0.76 $ ( 16.67 ) $ ( 0.16 ) $ ( 77.09 ) The following potentially dilutive outstanding securities were excluded from the computation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Series A-1 convertible preferred stock (as converted to Common Stock) - 4,000,000 - 4,000,000 Series A-2 convertible preferred stock (as converted to Common Stock) - 4,427,072 - 4,427,072 Series B convertible preferred stock (as converted to Common Stock) - 7,341,485 - 7,341,485 Series C convertible preferred stock (as converted to Common Stock) - 8,016,645 - 8,016,645 Series D convertible preferred stock (as converted to Common Stock) - 19,580,262 - 19,580,262 Warrants to purchase Common Stock - 226,196 242,924 226,196 Stock options to purchase Common Stock 1,529,195 7,748,938 9,512,706 7,748,938 Earn-out shares 7,536,461 - 7,536,461 - Total 9,065,656 51,340,598 17,292,091 51,340,598

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Equity Award Grants In November 2022, the Company granted 2,844,059 stock options and 858,559 restricted stock unit awards with various time-based vesting conditions pursuant to the 2022 Plan. Additionally, 4,554,408 restricted stock unit awards were granted to senior executives which shall vest upon the Company’s Common Stock achieving certain specified prices per share.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company, after elimination of all intercompany accounts and transactions. As permitted for interim reporting, certain footnotes or other financial information that are normally required by U.S. GAAP may be condensed or omitted, unless otherwise required by U.S. GAAP or Securities and Exchange Commission (“SEC”) rules and regulations. These condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with the Company’s annual consolidated financial statements included in the Company's final prospectus filed pursuant to Rule 424(b)(3) under the Securities Act with the SEC on October 17, 2022. In the opinion of management, all adjustments of a normal recurring nature, considered necessary for fair presentation, have been included in these condensed consolidated financial statements. The results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other interim period or future year. The condensed consolidated balance sheet as of December 31, 2021 was derived from the audited annual consolidated financial statements but does not include all information required by U.S. GAAP for annual consolidated financial statements.
Legacy Convertible Preferred Stock	Legacy Convertible Preferred Stock: In connection with the Business Combination, all Legacy Convertible Preferred Stock were converted to common stock of Legacy Akili. See Notes 1, 3, and 10 for further information. The Company recorded shares of Legacy Convertible Preferred Stock at their respective estimated fair values on the dates of issuance, net of issuance costs. Legacy Convertible Preferred Stock was classified outside of stockholders’ deficit because the holders of such shares had liquidation and redemption rights in the event of a deemed liquidation event that, in certain situations, are not solely within the control of the Company, such as a merger, acquisition, and sale of all or substantially all of the Company’s assets.
Earn-Out Liabilities	Earn-Out Liabilities: In connection with the Business Combination, holders of Legacy Akili common stock, Legacy Convertible Preferred Stock and warrants to purchase shares of Legacy Akili common stock ("Earn-Out Shareholders") and employees or individual service providers holding options to purchase shares of Legacy Akili common stock, in each case as designated by the Board of Akili as an earn-out service provider prior to the Closing Date (“Earn-Out Service Providers”) received the contingent right to receive additional Common Stock upon the achievement of certain earn-out targets (the “Rights”). The Company concluded the issuance of Rights to Earn-Out Shareholders constitutes a deemed dividend and evaluated the Rights for classification under guidance applicable to financial instruments. In assessing classification, the Company considered ASC Subtopic 815-40 “ Contracts in Entity’s Own Equity ” and determined the Rights contain settlement provisions that preclude them from being indexed to the Company’s stock and accordingly liability classification is required. The Company concluded issuance of the Rights to Earn-Out Service Providers represents compensation in scope of ASC Topic 718, " Compensation - Stock Compensation. " In considering relevant classification guidance, the Company determined the Rights issued to Earn-Out Service Providers are liabilities because they are indexed to whether such Earn-Out Service Providers hold qualifying equity instruments when the earn-out targets are achieved. The fair value of the contingent earn-out consideration is estimated as of the Closing Date at the present value of the expected contingent earn-out consideration using a Monte Carlo Simulation Method ("MCSM"). The Company reviews the probability of achievement of the earn-out targets to determine the impact on the fair value of the earn-out consideration on a quarterly basis over the earn-out period. For Earn-Out Shareholders, the corresponding fair value was initially recorded against additional paid-in capital. Changes in the estimated fair value of the contingent earn-out consideration related to Earn-Out Shareholders are recorded in other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) and are reflected in the period in which they are identified. For Earn-Out Service Providers, the corresponding fair value was initially recorded within operating expenses in the same functional category as the grantees' operating expenses. Changes in the estimated fair value of contingent earn-out consideration related to Earn-Out Service Providers is recorded as stock compensation for the period. Changes in the estimated fair value of the contingent earn-out consideration may materially impact or cause volatility in the Company's operating results.
Transaction Costs	Transaction Costs: The Company has allocated certain transaction costs to the Earn-out Shares based on the relative fair value of these instruments as compared to the other newly issued instruments as part of the Business Combination. The portion of transaction costs allocated to these instruments is reflected as a reduction to cash and an increase in selling, general and administrative expense. The costs were determined to relate to future share issuances and not to the initial recapitalization and therefore they were expensed on the Closing Date. All costs allocated to the other newly issued instruments, which consisted of Common Stock, were recorded in total permanent equity (deficit) as a reduction of additional paid-in capital.
Investments	Investments: The Company considers all investments with original maturities of more than three months but less than one year to be short-term investments. All investments in marketable securities are classified as available for sale. Available-for-sale securities are reported at fair value, with temporary unrealized gains and losses excluded from earnings and reported as a separate component of stockholders’ equity, while other-than-temporary gains or losses are included in earnings. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the condensed consolidated statements of operations and comprehensive income (loss).
Revenue	Revenue: The following table presents the Company’s revenue by type: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Product revenue $ 82 $ 57 $ 212 $ 123 Collaboration revenue - 98 - 254 Total $ 82 $ 155 $ 212 $ 377 As of September 30, 2022, the Company has a contract liability related to product revenue, which consists of amounts that have been paid but have not been recognized as revenue. All amounts are expected to be recognized as revenue within 12 months of the balance sheet date and are classified as current deferred revenue. The Company recognized $ 72 of product revenue in the nine months ended September 30, 2022 that was previously included in the December 31, 2021 deferred revenue balance. Contract Liabilities Product Balance at December 31, 2021 $ 96 Revenue recognized ( 212 ) Revenue deferred 225 Balance at September 30, 2022 $ 109
Advertising	Advertising: The Company expenses advertising costs as incurred. Advertising expenses were $ 464 and $ 6,401 during the three and nine months ended September 30, 2022. Advertising expenses were $ 4,893 and $ 7,760 during the three and nine months ended September 30, 2021 .
Leases	Leases: The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since it does not currently have a rating agency-based credit rating. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. The Company has elected the practical expedient not to separate lease and non-lease components for real estate leases.
Recently Adopted and Issued Accounting Pronouncements	Recently adopted accounting pronouncements: In February 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”), Leases (Topic 842) as amended by ASU 2019-10 and ASU 2020-05, which supersedes the guidance in former ASC Topic 840, Leases . The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less are not impacted by the new guidance. The Company adopted this guidance, effective January 1, 2022 , using the modified retrospective method as of the date of adoption such that prior periods will not be restated. The Company elected a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. Additional disclosures related to accounting for leases under this new standard are included in Note 5. The adoption incrementally increased the Company’s assets and liabilities by the right-of-use asset and lease liabilities. As the leases do not provide an implicit rate, the Company’s incremental borrowing rate was determined based on the information available at the date of adoption to measure its lease liability. The adoption did not have a material impact on the Company’s condensed consolidated statement of operations and comprehensive income (loss) and did not require a cumulative adjustment to accumulated deficit on its condensed consolidated statement of stockholders’ equity as of September 30, 2022. Recently issued accounting pronouncements: In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), as amended by ASU 2019-10. ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. ASU 2016-13 is effective for the Company for the annual reporting period beginning January 1, 2023. The Company is currently evaluating the potential impact this standard may have on its consolidated financial statements and results of operations. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes-Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This standard is effective for annual reporting periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. The Company is currently evaluating the potential impact that ASU 2019-12 will have on its consolidated financial statements and related disclosures; however, it does not expect the impact to be material.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Company's Revenue	The following table presents the Company’s revenue by type: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Product revenue $ 82 $ 57 $ 212 $ 123 Collaboration revenue - 98 - 254 Total $ 82 $ 155 $ 212 $ 377
Summary of Contract Liabilities	Contract Liabilities Product Balance at December 31, 2021 $ 96 Revenue recognized ( 212 ) Revenue deferred 225 Balance at September 30, 2022 $ 109

Business Combination (Tables)

Business Combination (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Schedule of Reconciles the Elements of Business Combination to Consolidated Statement of Cash Flows and Consolidated Statement of Changes in Equity	The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: Nine months ended September 30, 2022 Cash - SCS trust and cash (net of redemptions) $ 2,283 Cash - PIPE investors 162,000 Gross proceeds 164,283 Transaction related expenses and other costs paid at Closing (of which $ 8,850 represent the Company's transaction costs) ( 30,989 ) Transaction related expenses and other costs paid after Closing ( 449 ) Net proceeds from the Business Combination 132,845
Schedule of Number of Shares of Common Stock Outstanding Immediately Following Closing	The number of shares of Common Stock outstanding immediately following the Closing was as follows: Common Stock SCS public stockholders 227,522 SCS sponsor and independent director 6,890,000 Legacy Akili stockholders (1) 54,541,224 PIPE investors 16,200,000 Total shares of Common Stock immediately after Closing 77,858,746 (1) The number of Legacy Akili shares was determined from the shares of Legacy Akili shares outstanding immediately prior to the Closing converted at the Exchange Ratio of approximately 1.15 . The amount includes the cashless exercise of certain outstanding Akili Interactive Labs, Inc. warrants, which resulted in the issuance of 8,834 shares of Common Stock. All fractional shares were rounded down. Amount excludes the issuance of 7,536,461 Earn-Out Shares (as defined below), as the performance conditions have not yet been satisfied.
Schedule of Change in Fair Value Recorded as Stock Compensation	The change in fair value is recorded as stock compensation for the period in the same functional category as the grantees' operating expenses. Earn-Out Shareholders Earn-Out Service Providers Total Fair value as of December 31, 2021 $ - $ - $ - Initial fair value of earn-out liabilities at date of Business Combination 87,512 13,467 100,979 Change in fair value ( 77,892 ) ( 11,987 ) ( 89,879 ) Fair value as of September 30, 2022 $ 9,620 $ 1,480 $ 11,100

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Prepaid Expense Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: September 30, December 31, Deferred issuance costs $ - $ 572 Prepaid clinical trials 829 872 Prepaid insurance 2,107 81 Other current assets 1,650 975 Prepaid expenses and other current assets $ 4,586 $ 2,500

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following: September 30, December 31, Furniture and fixtures $ 184 $ 184 Computer equipment and software 477 443 Office equipment 60 60 Leasehold improvements 975 975 Capitalized internal-use software costs 427 427 Total property and equipment 2,123 2,089 Less: accumulated depreciation and amortization ( 1,127 ) ( 896 ) Property and equipment, net $ 996 $ 1,193

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Future Lease Payments for Noncancelable Operating Leases	Future lease payments for our noncancelable operating leases as of September 30, 2022 and a reconciliation to the carrying amount of the operating lease liability presented in the condensed consolidated balance sheet as of September 30, 2022 is as follows: Years Ending December 31, Amounts 2022 (remaining 3 months) $ 256 2023 1,042 2024 914 2025 950 2026 905 Total undiscounted payments due under operating leases 4,067 Less imputed interest ( 563 ) Total $ 3,504 Current operating lease liability $ 803 Non-current operating lease liability 2,701 Total $ 3,504 For comparable purposes, aggregate future minimum non-cancellable commitments under leases as of December 31, 2021, are as follows: Years Ending December 31, Amounts 2022 (remaining 3 months) $ 242 2023 878 2024 914 2025 950 2026 905 Total $ 3,889

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: September 30, December 31, Accrued bonus $ 2,592 $ 2,516 Accrued royalties 105 106 Accrued wages and benefits 714 421 Accrued clinical study expenses 416 363 Accrued consulting service expenses 702 766 Other accrued expenses 1,711 1,305 Total $ 6,240 $ 5,477

Corporate Bond (Tables)

Corporate Bond (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Carrying Amount of Corporate Bond	The carrying amount of the corporate bond is as follows: September 30, December 31, Corporate Bond $ 5,000 $ 5,000 Unamortized discount on Corporate Bond ( 3,215 ) ( 3,362 ) Corporate Bond, net of discount $ 1,785 $ 1,638

Note Payable (Table)

Note Payable (Table)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Carrying Amount of Note Payable	At September 30, 2022 , the carrying amount of the note payable (excluding the current portion of $ 2,500 ) is as follows: Outstanding principal $ 15,000 Note payable, short term ( 2,500 ) Final Payment 750 Unamortized debt issuance costs ( 814 ) Note payable, long term (net of debt issuance costs) $ 12,436
Future Minimum Principal Payments Due	Future minimum principal payments due under the Amended and Restated Loan and Security Agreement, excluding the Final Payment, are as follows: Years Ending December 31, Remainder of 2022 $ - 2023 4,375 2024 7,500 2025 3,125 Total $ 15,000

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Summary of Details of Legacy Convertible Preferred Stock Authorized Issued And Outstanding	The following table summarizes details of Legacy Convertible Preferred Stock authorized, issued and outstanding on the Closing Date immediately prior to the Business Combination: Legacy Convertible Preferred Series Par Value Authorized (1) Issued and Outstanding (1) Carrying Value (2) Series A-1 Convertible Preferred Stock $ 0.0001 4,604,762 4,604,762 $ — Series A-2 Convertible Preferred Stock 0.0001 5,096,403 5,096,403 7,128 Series B Convertible Preferred Stock 0.0001 8,451,448 8,451,448 41,854 Series C Convertible Preferred Stock 0.0001 9,228,686 9,228,686 67,904 Series D Convertible Preferred Stock 0.0001 20,721,430 15,936,919 186,065 Total 48,102,729 43,318,218 $ 302,951 (1) Shares authorized, shares issued and outstanding, and the conversion price/share have been adjusted to reflect the exchange of Legacy Convertible Preferred Stock for Akili, Inc. Common Stock at an exchange ratio of approximately 1.15 as a result of the Business Combination. (2) For the purpose of this calculation, the Series D redeemable convertible preferred stock continued to accrue dividends through the Closing Date and the adjusted total of Series D redeemable convertible preferred stock was multiplied by 150 % to determine the carrying value on the date of the Business Combination.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Summary of Stock-Based Compensation Expense	Stock-based compensation expense, including the expense related to Earn-Out Service Providers, is classified in the condensed consolidated statements of operations and comprehensive income (loss) as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ 1,312 $ 408 $ 2,762 $ 920 Selling, general and administrative 1,841 1,340 4,430 2,628 Total $ 3,153 $ 1,748 $ 7,192 $ 3,548
Summary of Stock Option Activity and Related Information	A summary of the Company’s stock option activity and related information is as follows: Number of Weighted- Weighted- Aggregate Balance at December 31, 2021 8,667,093 $ 3.38 7.28 Granted 1,536,102 $ 10.06 Cancelled ( 631,747 ) $ 3.94 Exercised ( 58,745 ) $ 2.49 Balance at September 30, 2022 9,512,703 $ 4.43 6.87 $ 1,052 Exercisable September 30, 2022 6,208,060 $ 3.34 5.86 $ 1,052 Options vested and expected to vest, September 30, 2022 9,512,703 $ 4.43 6.87 $ 1,052
Summary of Stock Option Activity Weighted-Average Assumptions	The fair value of all option activity was estimated at the date of grant using a Black-Scholes model with the following weighted-average assumptions for the nine months ended September 30, 2022 and 2021: Nine Months Ended 2022 2021 Fair value of Common Stock $ 10.06 $ 4.40 Expected volatility 96.21 % 98.73 % Expected term (in years) 6.03 4.88 Risk-free interest rate 1.73 % 0.81 % Expected dividend yield 0.00 % 0.00 %

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: Fair Value Measurements as of September 30, 2022 Description Level 1 Level 2 Level 3 Total Assets Cash equivalents: Money market funds $ 56,993 $ - $ - $ 56,993 Short-term investments: United States treasuries 66,696 - - 66,696 Total assets $ 123,689 $ - $ - $ 123,689 Long-term liabilities: Earn-out liabilities - - 11,100 11,100 Total liabilities $ - $ - $ 11,100 $ 11,100 Fair Value Measurements as of December 31, 2021 Description Level 1 Level 2 Level 3 Total Assets Cash equivalents: Money market funds $ 61,509 $ — $ — $ 61,509

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders	The computation of basic net income (loss) per share is based on the weighted-average number of our common shares outstanding. The computation of diluted net income (loss) per share is based on the weighted-average number of our common shares outstanding and potential dilutive common shares during the period as determined by the treasury stock method. The following table summarizes the computation of basic and diluted net income (loss) per share attributable to common stockholders of the Company: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator: Net income (loss) attributable to common stockholders - basic $ 50,839 $ ( 22,296 ) $ ( 2,224 ) $ ( 102,888 ) Dividends on Series D convertible preferred stock 1,598 - - - Redemption value of Series D convertible preferred stock 799 - - - Net income (loss) attributable to common stockholders - diluted $ 53,236 $ ( 22,296 ) $ — $ ( 2,224 ) $ ( 102,888 ) Denominator: Weighted average Common Stock outstanding - basic 36,920,116 1,337,797 13,690,186 1,334,562 Weighted average effect of potentially dilutive securities: Effect of potentially dilutive convertible preferred stock 28,695,420 - - - Effect of potentially dilutive warrants 122,713 - - - Effect of potentially dilutive stock options 4,092,721 - - - Total potentially dilutive securities 32,910,854 - - - Weighted average common stock outstanding - diluted 69,830,970 1,337,797 13,690,186 1,334,562 Net income (loss) per share attributable to common stockholders - basic $ 1.38 $ ( 16.67 ) $ ( 0.16 ) $ ( 77.09 ) Net income (loss) per share attributable to common stockholders - diluted $ 0.76 $ ( 16.67 ) $ ( 0.16 ) $ ( 77.09 )
Summary of Computation of Diluted Net Income (Loss) Per Share Attributable to Common Stockholders Including Anti-dilutive Effect	The following potentially dilutive outstanding securities were excluded from the computation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Series A-1 convertible preferred stock (as converted to Common Stock) - 4,000,000 - 4,000,000 Series A-2 convertible preferred stock (as converted to Common Stock) - 4,427,072 - 4,427,072 Series B convertible preferred stock (as converted to Common Stock) - 7,341,485 - 7,341,485 Series C convertible preferred stock (as converted to Common Stock) - 8,016,645 - 8,016,645 Series D convertible preferred stock (as converted to Common Stock) - 19,580,262 - 19,580,262 Warrants to purchase Common Stock - 226,196 242,924 226,196 Stock options to purchase Common Stock 1,529,195 7,748,938 9,512,706 7,748,938 Earn-out shares 7,536,461 - 7,536,461 - Total 9,065,656 51,340,598 17,292,091 51,340,598

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands		9 Months Ended	12 Months Ended
	Aug. 19, 2022 USD ($) shares	Sep. 30, 2022 USD ($) Segment $ / shares shares	Dec. 31, 2021 USD ($) $ / shares
Organization, Consolidation and Presentation of Financial Statements [Lite Items]
Number of business segments | Segment		1
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001
Cash and cash equivalents and short term investments		$ 156,357
Undrawn debt cash and cash equivalents and short term investments		15,000
Deferred payments		187	$ 187
Accumulated deficit		$ (223,473)	$ (226,114)
SCS
Organization, Consolidation and Presentation of Financial Statements [Lite Items]
Business combination, issuance of common shares | shares	8,834	16,200,000
Common stock, par value | $ / shares		$ 0.0001
Business acquisition share price | $ / shares		$ 10
Business combination amount		$ 162,000
Business combination merger included funds in trust account		164,283
Business combination, transaction costs	$ 31,438	$ 12,927
Business combination exchange ratio		115%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Company's Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenues	$ 82	$ 155	$ 212	$ 377
Product Revenue
Disaggregation Of Revenue [Line Items]
Revenues	$ 82	57	$ 212	123
Collaboration Revenue
Disaggregation Of Revenue [Line Items]
Revenues		$ 98		$ 254

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue, revenue recognized			$ (212)
Advertising Expense	$ 464	$ 4,893	$ 6,401	$ 7,760
Lease term description			Leases with terms greater than one-year are recognized on the consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates or abatements we expect to receive from the lessor.
Lease, option to extend			Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain.
ASU 2016-02
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022		Jan. 01, 2022
Change in accounting principle, accounting standards update, adopted	true		true
Change in accounting principle, accounting standards update, immaterial effect	true		true
Product Revenue
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue, revenue recognized			$ 72

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Contract Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 96
Revenue recognized	(212)
Revenue deferred	225
Ending balance	$ 109

Business Combination - Addition

Business Combination - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Aug. 19, 2022	Sep. 30, 2022
Business Acquisition [Line Items]
Earn-out shares, share price	$ 14.07	$ 2.26
SCS
Business Acquisition [Line Items]
Business combination, common stock exchange ratio	115%
Business combination, transaction related expenses and other costs	$ 31,438	$ 12,927
Business combination transaction cost paid		8,850
Business combination additional transaction costs paid		$ 4,077
SCS | Common Stock
Business Acquisition [Line Items]
Business combination, earn-out shares		7,536,461
Trading days		20 days
Consecutive trading day period		30 days
SCS | Common Stock | Tranche One
Business Acquisition [Line Items]
Earn-out shares, share price		$ 15
SCS | Common Stock | Tranche Two
Business Acquisition [Line Items]
Earn-out shares, share price		20
SCS | Common Stock | Tranche Three
Business Acquisition [Line Items]
Earn-out shares, share price		$ 30
SCS | Earn-out shares
Business Acquisition [Line Items]
Business combination, transaction related expenses and other costs	$ 3,046

Business Combination - Schedule

Business Combination - Schedule of Reconciles the Elements of Business Combination to Consolidated Statement of Cash Flows and Consolidated Statement of Changes in Equity (Details) - SCS $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Business Acquisition [Line Items]
Gross proceeds	$ 164,283
Transaction related expenses and other costs paid at Closing (of which $8,850 represent the Company's transaction costs)	30,989
Transaction related expenses and other costs paid after Closing	(449)
Net proceeds from the Business Combination	132,845
PIPE Investors
Business Acquisition [Line Items]
Gross proceeds	162,000
SCS Trust and Cash (Net of Redemptions)
Business Acquisition [Line Items]
Gross proceeds	$ 2,283

Business Combination - Schedu_2

Business Combination - Schedule of Reconciles the Elements of Business Combination to Consolidated Statement of Cash Flows and Consolidated Statement of Changes in Equity (Parenthetical) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
SCS
Business Acquisition [Line Items]
Business combination transaction cost paid	$ 8,850

Business Combination - Schedu_3

Business Combination - Schedule of Number of Shares of Common Stock Outstanding Immediately Following Closing (Details) - shares	Sep. 30, 2022	Aug. 19, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Common stock, shares outstanding	77,858,746		1,674,106
SCS
Business Acquisition [Line Items]
Common stock, shares outstanding		77,858,746
SCS | SCS Public Stockholders
Business Acquisition [Line Items]
Common stock, shares outstanding		227,522
SCS | SCS Sponsor and Independent Director
Business Acquisition [Line Items]
Common stock, shares outstanding		6,890,000
SCS | Legacy Akili stockholders
Business Acquisition [Line Items]
Common stock, shares outstanding		54,541,224
SCS | PIPE Investors
Business Acquisition [Line Items]
Common stock, shares outstanding		16,200,000

Business Combination - Schedu_4

Business Combination - Schedule of Number of Shares of Common Stock Outstanding Immediately Following Closing (Parenthetical) (Details) - Legacy Akili stockholders - shares	Aug. 19, 2022	Aug. 18, 2022
Business Acquisition [Line Items]
Business combination, common stock exchange ratio	115%	1.15%
Business combination, earn-out shares	7,536,461

Business Combination - Schedu_5

Business Combination - Schedule of Change in Fair Value Recorded as Stock Compensation (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Business Acquisition [Line Items]
Initial fair value of earn-out liabilities at date of Business Combination	$ 100,979
Change in fair value	(89,879)
Fair value as of September 30, 2022	11,100
Earn-Out Shareholders
Business Acquisition [Line Items]
Initial fair value of earn-out liabilities at date of Business Combination	87,512
Change in fair value	(77,892)
Fair value as of September 30, 2022	9,620
Earn-Out Service Providers
Business Acquisition [Line Items]
Initial fair value of earn-out liabilities at date of Business Combination	13,467
Change in fair value	(11,987)
Fair value as of September 30, 2022	$ 1,480

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expense Current [Abstract]
Deferred issuance costs		$ 572
Prepaid clinical trials	$ 829	872
Prepaid insurance	2,107	81
Other current assets	1,650	975
Prepaid expenses and other current assets	$ 4,586	$ 2,500

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment	$ 2,123	$ 2,089
Less: accumulated depreciation and amortization	(1,127)	(896)
Property and equipment, net	996	1,193
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment	184	184
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment	477	443
Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment	60	60
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	975	975
Capitalized Internal-Use Software Costs
Property Plant And Equipment [Line Items]
Property and equipment	$ 427	$ 427

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 77	$ 60	$ 231	$ 198

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) ft² Floor City	Sep. 30, 2022 USD ($) ft² Floor City	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) ft² Floor City	Sep. 30, 2021 USD ($)
Lessee Lease Description [Line Items]
Number of cities leases office space under operating leases operates | City	2	2		2
Rent expense		$ 262	$ 269	$ 786	$ 854
Net cash paid for operating lease liability				$ 630
Lease term	4 years	4 years		4 years
Operating lease borrowing rate	7.5	7.5		7.5
Security Deposit | Restricted Cash
Lessee Lease Description [Line Items]
Letter of credit	$ 250	$ 250		$ 250
Massachusetts
Lessee Lease Description [Line Items]
Number of rental floor | Floor	1	1		1
Lessee area of operating lease | ft²	4,000	4,000		4,000
Operating lease expiration period	2023-12
California
Lessee Lease Description [Line Items]
Lessee area of operating lease | ft²	43,600	43,600		43,600
Operating lease expiration period				2026-11

Leases - Future Lease Payments

Leases - Future Lease Payments for Noncancelable Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
2022 (remaining 3 months)	$ 256	$ 242
2023	1,042	878
2024	914	914
2025	950	950
2026	905	905
Total undiscounted payments due under operating leases	4,067
Less imputed interest	(563)
Total	3,504	$ 3,889
Current operating lease liability	803
Non-current operating lease liability	$ 2,701

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Accrued bonus	$ 2,592	$ 2,516
Accrued royalties	105	106
Accrued wages and benefits	714	421
Accrued clinical study expenses	416	363
Accrued consulting service expenses	702	766
Other accrued expenses	1,711	1,305
Total	$ 6,240	$ 5,477

Corporate Bond - Additional Inf

Corporate Bond - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Mar. 31, 2019
Debt Instrument [Line Items]
Corporate bond	$ 5,000		$ 5,000		$ 5,000
Corporate Bond Securities
Debt Instrument [Line Items]
Amortization expense	$ 50	$ 44	$ 147	$ 131
Corporate Bond Securities | Shinogi And Company Limited | Option And Collaboration Agreement
Debt Instrument [Line Items]
Corporate bond						$ 5,000

Corporate Bond - Schedule Of Su

Corporate Bond - Schedule Of Subordinated Borrowing (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Subordinated Borrowings [Abstract]
Corporate bond	$ 5,000	$ 5,000
Unamortized discount on corporate bond	(3,215)	(3,362)
Corporate bond, net of discount	$ 1,785	$ 1,638

Note Payable - Additional Infor

Note Payable - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jun. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Interest expense, debt		$ 496	$ 172	$ 866	$ 292
Interest rate		10%		10%
Note payable, short term		$ 2,500		$ 2,500
Loan and Security Agreement
Debt Instrument [Line Items]
Loan additional drew capacity	$ 10,000
Outstanding principal repayment	15,000
Debt frequency of payment				24 equal monthly payments
Additional loan borrowed	10,000
Debt issuance costs	$ 500
Outstanding principal amount		$ 15,000		$ 15,000
Interest expense, debt				$ 178

Note Payable - Schedule of Carr

Note Payable - Schedule of Carrying Amount of Note Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Note payable, short term	$ (2,500)
Note payable, long term (net of debt issuance costs)	12,436	$ 4,784
Note Payable
Debt Instrument [Line Items]
Outstanding principal	15,000
Note payable, short term	(2,500)
Final Payment	750
Unamortized debt issuance costs	(814)
Note payable, long term (net of debt issuance costs)	$ 12,436

Note Payable - Future Minimum P

Note Payable - Future Minimum Principal Payments Due (Details) - Loan and Security Agreement $ in Thousands	Sep. 30, 2022 USD ($)
Debt Instrument [Line Items]
2023	$ 4,375
2024	7,500
2025	3,125
Outstanding principal	$ 15,000

Capital Stock - Additional Info

Capital Stock - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Aug. 18, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common stock, shares authorized	1,000,000,000		63,315,481
Common stock, par value	$ 0.0001		$ 0.0001
Redeemable convertible preferred stock, shares authorized	100,000,000	48,102,729	48,102,729
Redeemable convertible preferred stock, par value	$ 0.0001		$ 0.0001
Common stock, shares issued	77,858,746		1,674,106
Common stock, shares outstanding	77,858,746		1,674,106
Warrants outstanding to purchase common stock	242,924
Redeemable convertible preferred stock, shares issued	0	43,318,218	43,318,218
Redeemable convertible preferred stock, shares outstanding	0	43,318,218	43,318,218
Number of vote for each share of common stock	1
Threshold gross proceeds for mandatory conversion	$ 75,000,000
2022 Employee Stock Purchase plan
Class of Stock [Line Items]
Common stock, shares issued	0
Percentage of lower of fair market value of stock	85%
Maximum offering period	27 months
Limitation on employee payroll deductions percentage	15%
Employee purchase of stock maximum amount	$ 25,000
Common stock reserved for future issuance	1,167,881
Percentage of outstanding shares issued and outstanding	1%
Series A-1 Convertible Preferred Stock
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized		4,604,762
Redeemable convertible preferred stock, par value		$ 0.0001
Redeemable convertible preferred stock, shares issued		4,604,762
Redeemable convertible preferred stock, shares outstanding		4,604,762
Temporary equity conversion price per share	$ 1
Series A-2 Convertible Preferred Stock
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized		5,096,403
Redeemable convertible preferred stock, par value		$ 0.0001
Redeemable convertible preferred stock, shares issued		5,096,403
Redeemable convertible preferred stock, shares outstanding		5,096,403
Temporary equity conversion price per share	1.995
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized		8,451,448
Redeemable convertible preferred stock, par value		$ 0.0001
Redeemable convertible preferred stock, shares issued		8,451,448
Redeemable convertible preferred stock, shares outstanding		8,451,448
Temporary equity conversion price per share	5.7699
Series C Convertible Preferred Stock
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized		9,228,686
Redeemable convertible preferred stock, par value		$ 0.0001
Redeemable convertible preferred stock, shares issued		9,228,686
Redeemable convertible preferred stock, shares outstanding		9,228,686
Temporary equity conversion price per share	8.5073
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized		20,721,430
Redeemable convertible preferred stock, par value		$ 0.0001
Redeemable convertible preferred stock, shares issued		15,936,919
Redeemable convertible preferred stock, shares outstanding		15,936,919
Temporary equity conversion price per share	$ 8.426854

Capital Stock - Summary of Deta

Capital Stock - Summary of Details of Legacy Convertible Preferred Stock Authorized Issued And Outstanding (Details) - USD ($)	Sep. 30, 2022	Aug. 18, 2022	Dec. 31, 2021
Temporary Equity [Line Items]
Par Value	$ 0.0001		$ 0.0001
Authorized	100,000,000	48,102,729	48,102,729
Issued	0	43,318,218	43,318,218
Outstanding	0	43,318,218	43,318,218
Carrying Value		$ 302,951	$ 291,876,000
Series A-1 Convertible Preferred Stock
Temporary Equity [Line Items]
Par Value		$ 0.0001
Authorized		4,604,762
Issued		4,604,762
Outstanding		4,604,762
Series A-2 Convertible Preferred Stock
Temporary Equity [Line Items]
Par Value		$ 0.0001
Authorized		5,096,403
Issued		5,096,403
Outstanding		5,096,403
Carrying Value		$ 7,128
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Par Value		$ 0.0001
Authorized		8,451,448
Issued		8,451,448
Outstanding		8,451,448
Carrying Value		$ 41,854
Series C Convertible Preferred Stock
Temporary Equity [Line Items]
Par Value		$ 0.0001
Authorized		9,228,686
Issued		9,228,686
Outstanding		9,228,686
Carrying Value		$ 67,904
Series D Convertible Preferred Stock
Temporary Equity [Line Items]
Par Value		$ 0.0001
Authorized		20,721,430
Issued		15,936,919
Outstanding		15,936,919
Carrying Value		$ 186,065

Capital Stock - Summary of De_2

Capital Stock - Summary of Details of Legacy Convertible Preferred Stock Authorized Issued And Outstanding (Parenthetical) (Details)	Aug. 18, 2022
Series D Convertible Preferred Stock
Temporary Equity [Line Items]
Percentage to determine carrying value	150%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Stock-based compensation	$ 3,153	$ 1,748	$ 7,192	$ 3,548
Expiration period (in years)			10 years
Vesting period			4 years
Weighted average grant-date fair value of stock options granted to employees			$ 7.79	$ 3.39
Aggregate intrinsic value of stock option awards exercised			$ 445	$ 327
Earn-Out Shares to Earn-Out Service Provider
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Stock-based compensation	$ 1,480		$ 1,480
2022 Stock Option and Incentive Plan
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Common stock reserved for future issuance	12,813,781		12,813,781
Unrecognized compensation cost related to unvested stock option grants to employees	$ 14,203		$ 14,203
Unrecognized compensation cost, expected to be recognized over a weighted-average period			2 years 10 months 24 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 3,153	$ 1,748	$ 7,192	$ 3,548
Research and Development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	1,312	408	2,762	920
Selling, General and Administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 1,841	$ 1,340	$ 4,430	$ 2,628

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 $ / shares shares
Equity [Abstract]
Number of Options, Beginning Balance | shares	8,667,093
Number of Options, Granted | shares	1,536,102
Number of Options, Cancelled | shares	(631,747)
Number of Options, Exercised | shares	(58,745)
Number of Options, Ending Balance | shares	9,512,703	8,667,093
Number of Options, Exercisable | shares	6,208,060
Number of Options, Options Vested and Expected to Vest | shares	9,512,703
Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 3.38
Weighted Average Exercise Price Per Share, Granted | $ / shares	10.06
Weighted Average Exercise Price Per Share, Cancelled | $ / shares	3.94
Weighted Average Exercise Price Per Share, Exercised | $ / shares	2.49
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares	4.43	$ 3.38
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	3.34
Weighted Average Exercise Price Per Share, Options Vested and Expected to Vest | $ / shares	$ 4.43
Weighted Average Remaining Contractual Term (in Years), Balance	6 years 10 months 13 days	7 years 3 months 10 days
Weighted Average Remaining Contractual Term (in Years), Exercisable	5 years 10 months 9 days
Weighted Average Remaining Contractual Term (in Years), Options vested and expected to vest	6 years 10 months 13 days
Aggregate Intrinsic Value, Balance | $	$ 1,052
Aggregate Intrinsic Value, Exercisable | $	1,052
Aggregate Intrinsic Value, Options vested and expected to vest | $	$ 1,052

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock Option Activity Weighted Average Assumptions (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Fair value of common stock	$ 10.06	$ 4.40
Expected volatility	96.21%	98.73%
Expected term (in years)	6 years 10 days	4 years 10 months 17 days
Risk-free interest rate	1.73%	0.81%
Expected dividend yield	0%	0%

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities - Fair Value of Assets and Liabilities on a Recurring Basis (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Assets
Short-term investments	$ 66,696,000
Fair Value, Measurements, Recurring
Assets
Total assets	123,689,000
Long-term liabilities:
Total liabilities	11,100,000	$ 0
Fair Value, Measurements, Recurring | Earn-Out Liabilities
Long-term liabilities:
Total liabilities	11,100,000
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1
Assets
Total assets	123,689,000
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3
Long-term liabilities:
Total liabilities	11,100,000
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | Earn-Out Liabilities
Long-term liabilities:
Total liabilities	11,100,000
Fair Value, Measurements, Recurring | Money Market Funds
Assets
Cash equivalents	56,993,000	61,509,000
Fair Value, Measurements, Recurring | Money Market Funds | Fair Value, Inputs, Level 1
Assets
Cash equivalents	56,993,000	$ 61,509,000
Fair Value, Measurements, Recurring | US Treasury Securities
Assets
Short-term investments	66,696,000
Fair Value, Measurements, Recurring | US Treasury Securities | Fair Value, Inputs, Level 1
Assets
Short-term investments	$ 66,696,000

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Aug. 19, 2022
Business Acquisition [Line Items]
Fair value, transfers of financial instruments between levels		$ 0	$ 0
Unrealized gains on short-term Investments in other comprehensive loss	$ 14,000	$ 7,000
Earn-out shares, share price	$ 2.26	$ 2.26			$ 14.07
Earn-out shares, expected term	5 years	5 years
Earn-out shares, expected volatility rate	97.50%	97.50%			100%
Earn-out shares, expected dividend yield	0%	0%
Triggering Event I
Business Acquisition [Line Items]
Earn-out shares, share price	$ 15	$ 15
Triggering Event II
Business Acquisition [Line Items]
Earn-out shares, share price	20	20
Triggering Event III
Business Acquisition [Line Items]
Earn-out shares, share price	$ 30	$ 30
Fair Value, Measurements, Recurring
Business Acquisition [Line Items]
Liabilities, fair value	$ 11,100,000	$ 11,100,000		$ 0
Short-Term Investments
Business Acquisition [Line Items]
Unrealized gains on short-term Investments in other comprehensive loss		$ 7,000
Short-Term Investments | US Treasury Securities | Maximum
Business Acquisition [Line Items]
Original maturities term of investments from date of purchase		1 year		1 year
Short-Term Investments | US Treasury Securities | MinimumMember
Business Acquisition [Line Items]
Original maturities term of investments from date of purchase		3 months		3 months
Cash And Cash Equivalents | Money Market Funds | Maximum
Business Acquisition [Line Items]
Original maturities term of investments from date of purchase		90 days		90 days

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Summary of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net income (loss) per share attributable to common stockholders - basic	$ 50,839	$ (22,296)	$ (2,224)	$ (102,888)
Dividends on Series D convertible preferred stock	1,598
Redemption value of Series D convertible preferred stock	799	1,386	3,692	57,263
Net income (loss) attributable to common stockholders - diluted	$ 53,236	$ (22,296)	$ (2,224)	$ (102,888)
Denominator:
Weighted average common shares outstanding, Basic	36,920,116	1,337,797	13,690,186	1,334,562
Weighted average effect of potentially dilutive securities:
Effect of potentially dilutive convertible preferred stock	28,695,420
Effect of potentially dilutive stock options	4,092,721
Effect of potentially dilutive warrants	122,713
Total potentially dilutive securities	32,910,854
Weighted average common shares outstanding, Diluted	69,830,970	1,337,797	13,690,186	1,334,562
Net income (loss) per share attributable to common stockholders - basic	$ 1.38	$ (16.67)	$ (0.16)	$ (77.09)
Net income (loss) per share attributable to common stockholders - diluted	$ 0.76	$ (16.67)	$ (0.16)	$ (77.09)

Net Income (Loss) Per Share -_2

Net Income (Loss) Per Share - Summary of Computation of Diluted Net Income (Loss) Per Share Attributable to Common Stockholders Including Anti-dilutive Effect (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	9,065,656	51,340,598	17,292,091	51,340,598
Series A-1 Convertible Preferred Stock (as Converted to Common Stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		4,000,000		4,000,000
Series A-2 Convertible Preferred Stock (as Converted to Common Stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		4,427,072		4,427,072
Series B Convertible Preferred Stock (as Converted to Common Stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		7,341,485		7,341,485
Series C Convertible Preferred Stock (as Converted to Common Stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		8,016,645		8,016,645
Series D Convertible Preferred Stock (as Converted to Common Stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		19,580,262		19,580,262
Warrants to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		226,196	242,924	226,196
Stock Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	1,529,195	7,748,938	9,512,706	7,748,938
Earn-out shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	7,536,461		7,536,461

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - shares		9 Months Ended
	Nov. 14, 2022	Sep. 30, 2022
Subsequent Event [Line Items]
Awards granted		1,536,102
Stock Options | 2022 Stock Option and Incentive Plan | Subsequent Event
Subsequent Event [Line Items]
Awards granted	2,844,059
Restricted Stock Units (RSUs) | 2022 Stock Option and Incentive Plan | Subsequent Event
Subsequent Event [Line Items]
Restricted awards granted	858,559
Restricted Stock Units (RSUs) | Senior Executives | 2022 Stock Option and Incentive Plan | Subsequent Event
Subsequent Event [Line Items]
Restricted awards granted	4,554,408